As shown in Figure 4, serum Gal-9 (Figure 4A) and FABP1 (Figure 4B) levels significantly declined (3.72 ng/mL, IQR 2.78–5.59 ng/mL versus 2.10 ng/mL, IQR 1.84–2.67 ng/mL, p < 0.001; 1.72 ng/mL, IQR 0.66–4.55 ng/mL versus 0.77 ng/mL, IQR 0.31–4.51 ng/mL, p < 0.01, respectively), paralleling the reduction of RA disease activity, reflected by DAS28-ESR scores (Figure 4C) (mean ± standard deviation, 3.66 ± 1.31, 2.73 ± 0.42, p < 0.001) in patients receiving 12 months of b/tsDMARDs therapy. This evidence concerns the gene LGALS9 and rheumatoid arthritis.